Tag:

Chris Viehbacher

Latest Headlines

Latest Headlines

Sanofi execs prep their pitch on a post-Viehbacher R&D strategy

One of the primary roles for any Big Pharma CEO is to act as a chief defender of the pipeline. Just months ago, Chris Viehbacher boldly asserted that Sanofi had one of the top 5 pipelines in the industry, if you added in some top programs among its close development partners.

Need more on ex-Sanofi CEO Viehbacher's sudden exit?

If you haven't yet read enough about ex-Sanofi CEO Chris Viehbacher's departure, check out Bloomberg' s latest.

Ex-Sanofi CEO Viehbacher in line for up to $7.8M cash payoff

For the now-former chief of Sanofi, Chris Viehbacher, there's plenty of money for a cushion, but it won't be nearly as plump as the packages granted to his counterparts in the U.S.

Sanofi CEO Chris Viehbacher gets the boot: What happens next in R&D?

Chris Viehbacher took the helm of Sanofi with one clear message about the future: R&D at the Big Pharma had to undergo a radical restructuring. The lost decade in drug development following 2000 proved that Sanofi and others had to mend their ways, he said, forcing the company to reach outside the organization for innovation and shed the dead wood that had accumulated in its research ops.

Sanofi canned its outspoken CEO. Will the board go French with a replacement?

CEO Chris Viehbacher's future may not have been on the Sanofi board's agenda Monday. But it was on Wednesday. The directors issued a statement after an 8 a.m. meeting, the gist of which is this: At Sanofi, he has none.

Sanofi CEO: No deals? No problem

Pharma is riding an M&A deal wave like none the industry has ever seen, with companies looking to shed noncore businesses and bulk up in areas they want to focus on. But Sanofi? Not interested, CEO Chris Viehbacher says.

Sanofi CEO: M&A's just too expensive nowadays

Don't expect Sanofi's Chris Viehbacher to bring a shopping cart when he settles into his new home in the biopharma hub of Boston, as the CEO tells Bloomberg that he'd rather stand pat with his pipeline than pay a premium inflated by the recent biotech boom.

Sanofi CEO Viehbacher now calls beloved Boston biotech hub his home

As CEO of Paris-based Sanofi, Chris Viehbacher has never made any secret of his crush on the Boston-area biotech hub. He paid $20 billion for Genzyme, recently bought into Cambridge, MA-based Alnylam, partnered locally and made regular appearances in local industry circles.

Sanofi bucks unit-sale trend with plan to unload $7B worth of older products

While other companies are hiving off large pieces of their operations to get fit and focused, Sanofi has decided to simply clean out its closet.

Sanofi takes a more subdued approach by unloading older products

While other companies are hiving off large pieces of their operations to get fit and focused, Sanofi has decided just to clean out its closet. By selling off a number of older products, it can make room for the kind of bolt-on deals CEO Chris Viehbacher on Tuesday said interest him.